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A B S T R A C T
Mouse models of human cancers may provide a valuable resource for the discovery of can-
cer biomarkers. We have developed a practical strategy for profiling specific proteins in
mouse plasma using low-volume sandwich-immunoassays. We used this method to pro-
file the levels of 14 different cytokines, acute-phase reactants, and other cancer markers
in plasma from mouse models of intestinal tumors and their wild-type littermates, using
as little as 1.5 ml of diluted plasma per assay. Many of the proteins were significantly and
consistently up-regulated in the mutant mice. The mutant mice could be distinguished
nearly perfectly from the wild-type mice based on the combined levels of as few as three
markers. Many of the proteins were up-regulated even in the mutant mice with few or no
tumors, suggesting the presence of a systemic host response at an early stage of cancer de-
velopment. These results have implications for the study of host responses in mouse
models of cancers and demonstrate the value of a new low-volume, high-throughput sand-
wich-immunoassay method for sensitively profiling protein levels in cancer.
ª 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction
Proteomics technologies hold great potential for the discovery
of cancer biomarkers (Etzioni et al., 2003). While proteomics
technologies have significantly and steadily advanced in re-
cent years, the identification of low-abundance cancer
markers amidst complex backgrounds of high-abundance
and highly variable proteins has been difficult. An approach
to overcoming the problem of variability between specimens
and conditions is to use animal models of cancer (Kuick
et al., 2007; Shaw et al., 2005). Genetic backgrounds and envi-
ronmental and sample collection conditions can be precisely
controlled in animal models, which reduces the normalvariability between subjects and permits easier identification
of cancer-related protein alterations. Mass-spectrometry-
based studies of the proteomes of mouse models of cancer
are currently underway.
Antibody-based methods are a useful complement to
mass-spectrometry- and separations-based technologies. For
proteomics studies in mouse models of cancer, the ability to
analyze multiple proteins using low sample volumes would
be particularly useful. Many groups have demonstrated the
use of antibody microarrays as a means to multiplex the de-
tection of specific proteins (see reviews in Haab, 2006; King-
smore, 2006; Wingren and Borrebaeck, 2006). Although
significant progress in these technologies has been made,* Corresponding author. Tel.: þ1 616 234 5268; fax: þ1 616 234 5269.
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mics studies has yet to be established.
One approach tomultiplexing antibody assays is to directly
label all the proteins in a sample with a tag (such as biotin or
Cy3) and detect the level of tag bound at each antibody after
incubation of the sample on an antibody array (Haab et al.,
2001; Sreekumar et al., 2001; Wingren et al., 2005). This
method is simple and efficient for broad screening and discov-
ery, but is not as effective for the quantitative and highly-spe-
cific detection of a set of candidate markers. Sandwich assays
provide highly sensitive and specific detection and have been
multiplexed on microarrays (Huang et al., 2001; Schweitzer
et al., 2002; Li and Reichert, 2003; Geierstanger et al., 2006).
In this approach, the amount of protein bound to each capture
antibody on an array is probed with a labeled detection anti-
body, and multiple, different detection antibodies are mixed
into one solution. A limitation of this approach is the difficulty
in identifying matched capture and detection antibody pairs
that demonstrate no cross reactivity between proteins or anti-
bodies. Systematic routines have been worked out for screen-
ing for cross-reactivity among a set of purified proteins (Perlee
et al., 2004), but such tests do not rule out the possibility of
cross-reactivity in certain biological samples due to the occa-
sional presence of large protein complexes. Also, optimal
sample dilution factors might not be equivalent between cer-
tain analytes, making their multiplexed detection in a single
assay difficult. Sandwich assays also have been multiplexed
using bead-based assays (Vignali, 2000), which have similar
constraints and added concerns over potential interactions
between different capture antibodies in the same mixture.
One goal of this work was to develop an antibody-based
tool that is well-suited to the rapid and routine measurement
of specific protein levels in mouse models of cancers. Rather
than multiplexing sandwich assays in a single assay, we de-
tect single analytes in each assay, and use low-volume,
high-throughput methods so that many individual assays
can be run. In this way, the total sample volume consumed
is similar to the multiplexed approach, and the time per assay
can be made similar, while eliminating the possibility of
cross-reactivity and reducing the time of developing and vali-
dating the multiplexing. This approach was made possible by
the development of a versatile and practical method to pro-
cessmultiple arrays of varying sizes on eachmicroscope slide.
A second goal of this work was to apply this method to
measuringmultiple, specific proteins in the plasmaof amouse
model of human cancer. We used a murine intestinal tumor
model which carries a single-codon mutation in the Adeno-
matous Polyposis Coli (APC) gene and reliably develops 30–40
intestinal adenomas by 4 months of age (Su et al., 1992). The
APC gene has been established to be themost important initial
mutation for entry into the adenoma-carcinoma pathway,
and germline mutation in the human APC gene results in
the CRC predisposition syndrome Familial Adenomatous Pol-
yposis (FAP) (Kinzler and Vogelstein, 1996). Previous proteo-
mics profiling of plasma from this model showed significant
protein elevations relative to the wildtype counterpart mice
(Hung et al., 2006). As initial targets for the antibody arrays,
we chose proteins that could have altered levels in the plasma
after the onset of intestinal cancer, including inflammatory
cytokines, acute-phase reactants, and themucinMUC1. Theseproteins allowed us to test the ability of our system to detect
changes in protein expression in mouse plasma and to profile
the extent of a systemic host response in this mouse model,
which may be useful for later studies on those systems.
Also, we chose both high-abundance and low-abundance
proteins to test the performance of the method for a wide
range of targets.
2. Results
2.1. Development of low-volume, high-throughput
sandwich assays
In order to efficiently process many low-volume antibody ar-
rays, we used a custom-made device to imprint wax patterns
onto the surfaces of microscope slides, creating hydrophobic
partitions that segregate various samples (Figure 1a). Distinct
stamp designs can be used to form differing sizes and num-
bers of partitions on each slide. For this study, we used a de-
sign that partitions 48 arrays on each slide, with each array
composed of up to 144 distinct spots, and another design
that partitions 192 arrays on each slide, with each array con-
taining up to 12 spots. The larger array requires 6 ml of sample
per array, and the smaller requires 1.5 ml of sample per array.
The spacing of the arrays has been made compatible with
standard multi-channel pipettes for eventual automation.
Such a design enables the efficient processing of many
samples or conditions in parallel, using small volumes per as-
say. For the experiments described below, we used eight of the
arrays on each slide for calibration standards with known
concentrations of a particular analyte, and we used the rest
of the arrays for samples (Figure 1b). A single detection anti-
body then detected the level of an analyte on each slide. Since
we spotted multiple capture antibodies but used only a single
detection antibody on each array, only the capture antibody
corresponding to the detection antibody was used to measure
the level of the analyte, and the other antibodies served as
negative controls (Figure 1c).
Pairs of capture and detection antibodies were tested for
each target using serial dilutions of antigens (Figure 2). We
used dilutions of purified antigen if the antigen was commer-
cially available (11 targets), and we used dilutions of pooled
mouse plasma if not (9 targets). In ten cases, two different an-
tibodies were available as the capture and detection anti-
bodies, but for the other cases, only one antibody was
available, and that antibody was used both as capture and de-
tection (Table 1). Of the 20 sandwich assays for which we
attempted development, 14 produced sigmoidal binding
curves that indicated proper antibody–antigen interactions
(representative curves shown in Figure 2). For three of the
attempted assays we used antibodies that were raised against
human antigens, to test whether the cross-reactivity to the
mouse sequence would be sufficient to achieve antigen bind-
ing in pooled plasma. None of those assays showed signal. The
other three failed assays used antibodies that were raised
against mouse sequences but showed flat binding curves. A
summary of the attempted assays and results is provided in
Table 2.
M O L E C U L A R O N C O L O G Y 1 ( 2 0 0 7 ) 2 1 6 – 2 2 5218Figure 1 – An approach to high-throughput sample processing. (a) Wax is imprinted onto a microscope slide to form borders around multiple
arrays. Wax is melted by the hotplate under the bath, and a slide is inserted upside-down into the holder. Bringing the lever forward raises
a stamp out of the wax bath to touch the slide, imprinting the design onto the slide. Two stamps are shown in front of the device (left image). The
arrays are spaced by 4.5 mm, which is compatible with the 9 mm spacing of standard multi-channel pipettes (middle). Samples loaded onto
slides containing 12, 48, and 192 (96 samples loaded) arrays per slide are shown (right image). (b) A plan for incubating 40 different samples and
eight standards on one slide, with detection by a single detection antibody. (c) Schematic illustration of a sandwich assay with fluorescence
detection. Two different antibodies on an array are illustrated, and the detection antibody binds only its targeted protein bound by the
corresponding capture antibody.The detection limits determined from the dilution curves
that used purified antigens ranged from 50 pg/ml to low pg/
ml (Table 2 and Figure 2). These detection limits are similar
to those achieved for sandwich enzyme-linked immunosor-
bent assays (ELISA) and should be sufficient to detect most
cytokines, especially when elevated. The curves using dilu-
tions of serum can be used to set a proper dilution factor for
the individual samples. The dilution factor should be set so
that most individual measurements fall in the linear range
of the binding curve. For proteins with high endogenous con-
centrations like haptoglobin and hemopexin, we determined
dilution factors of 10,000 and 100,000, respectively, but formid-range proteins like CRP and plasminogen, we used dilu-
tion factors of 200 and 1000, respectively. We used a dilution
factor of 2 for all the cytokines.
2.2. Profiling protein levels in mutant and wildtype mice
We next determined the levels of the 14 proteins in individual
plasma samples from a cohort ofmutant (n ¼ 39) andwildtype
(n ¼ 25) mice. Two types of mutant mice were used, one with
a nonsense mutation at codon 850 of the APC gene (APCMin,
n ¼ 15), and the other with a nonsense mutation at codon
580 of the APC gene (APC D580, n ¼ 24). We ran the samples
MO L E C U L A R O N C O L O G Y 1 ( 2 0 0 7 ) 2 1 6 – 2 2 5 219Figure 2 – Standard curves of selected microarray analytes. Calibration curves were created by plotting the raw fluorescence signal (arbitrary
units) against the concentration of purified antigens (pg/ml) or against the dilution factor of pooled mouse plasma sample. The zero-concentration
data point is not included because of the log-scale on the x-axis.in a different, randomized order on themicroscope slideswith
each assay, along with a dilution curve of either purified anti-
gen or pooled plasma. The dilution curve provided a means to
convert the raw fluorescence values to concentration (if dilu-
tions of purified antigen were used) or to concentration units
(if dilutions of pooled plasma were used). We used the 48-ar-
ray format for seven of the assays and the 192-array format
for ten, with both formats for three.We investigated the agreement between the larger array
format, using 6 ml per array, and the smaller array format, us-
ing just 1.5 ml per array, for measurements of the protein IL-12
with arrays that were printed and run in the same batch. The
results showed a significant correlation over all the samples
(r ¼ 0.85) between the two formats (Figure 3b), indicating
a general correspondence in the assays. The correlation be-
tween the standard curves was very high (r ¼ 0.99, data not
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Capture/detection Source Catalog number
Antibody
Anti-human sialyl Lewis A Both Abcam ab3982
Anti-human tenascin C Both R & D Systems Mab2138
Anti-human von Willebrand factor Both DAKO A0082
Anti-mouse alpha 1 antitrypsin Both Abcam Ab14226
Anti-mouse clusterin Both R & D Systems AF2747
Anti-mouse CRP Both R & D Systems AF1829
Anti-mouse cytochrome c Capture BD Pharmingen 556432
Anti-mouse cytochrome c-biotinylated Detection BD Pharmingen 556432
Anti-mouse haptoglobin Both Life Diagnostics 18141
Anti-mouse hemopexin Both Immunology Consultants Laboratory CHX90A
Anti-mouse IL-10 Capture BD Pharmingen 551215
Anti-mouse IL-10-biotinylated Detection BD Pharmingen 554465
Anti-mouse IL-12 Capture BD Pharmingen 551219
Anti-mouse IL-12-biotinylated Detection BD Pharmingen 554476
Anti-mouse IL-1a Capture BD Pharmingen 550604
Anti-mouse IL-1a-biotinylated Detection BD Pharmingen 550606
Anti-mouse IL-1b Capture BD Pharmingen 550605
Anti-mouse IL-1b-biotinylated Detection R & D Systems BAF401
Anti-mouse IL-2 Capture BD Pharmingen 554424
Anti-mouse IL-2-biotinylated Detection BD Pharmingen 554426
Anti-mouse IL-6 Capture BD Pharmingen 554400
Anti-mouse IL-6 -biotinylated Detection BD Pharmingen 554402
Anti-mouse MCP-1 Capture BD Pharmingen 551217
Anti-mouse MCP-1-biotinylated Detection BD Pharmingen 554444
Anti-mouse MUC-1 Both Genway A22681
Anti-mouse plasminogen Both Oxford Biomedical Research PL64
Anti-mouse troponin C Both Biodesign H86742
Anti-mouse VEGF Capture R & D Systems AF493NA
Anti-mouse VEGF-biotinylated Detection R & D Systems BAF493
Protein
Alpha-1-antitrypsin Recombinant protein Research Diagnostics AB14226
Cytochrome c Recombinant protein R & D Systems 709cc
IL-10 Recombinant protein BD Pharmingen 550070
IL-12 Recombinant protein R & D Systems 419ML
IL-1a Recombinant protein R & D Systems 400ML
IL-1b Recombinant protein BD Pharmingen 554577
IL-2 Recombinant protein R & D Systems 402ML
IL-6 Recombinant protein BD Pharmingen 554582
MCP-1 Recombinant protein BD Pharmingen 554590
Troponin C Recombinant protein Biodesign A86562M
VEGF Recombinant protein Biodesign A52532Mshown), probably due to the lack of a complex background and
indicating that antibody spotting or binding is not the main
source of variability between assays. The intra-assay variabil-
ity was slightly higher for the smaller format, with a median
coefficient of variation (CV) between replicate antibody spots
of 11% for the smaller array versus 9% for the larger array.
The median CV between the formats was 18%, reflecting the
contributions of the separate sources of variability.
The mutant mice had higher levels of most of these pro-
teins than the wildtype mice, with very high statistical signif-
icance (Figure 3a). Themost consistently elevated protein was
CRP, which was elevated in cancer with a 90% sensitivity at an
80% specificity. An elevation in haptoglobin, hemopexin, and
plasminogen in this mouse model (using different samples)
was previously seen using mass spectrometry methods
(Hung et al., 2006).
The mice had variable numbers of tumors in the intestinal
tract at the time of sample collection, and the number oftumors generally increased with the age of the mice. We cor-
related the concentrations of the proteins with the number of
tumors and age of the mice to investigate the relationship
between those parameters (Table 3). In the mutant mice,
only IL-6, IL-12, haptoglobin, and hemopexin showed signifi-
cant correlations with age or number of tumors. None of those
proteins showed correlation with age in the wildtypemice, in-
dicating that the elevations in these proteins was not related
to the age of themice but rather to the presence of the tumors.
No proteins showed statistically significant differences
between the APCMin and APC D580 mice. The values from
MUC1 and IL-1beta were removed because a high percentage
of the samples gave a fluorescence signal below that of the
lowest standard.
A view of the patterns of protein level ordered by number
of tumors shows that for IL-6, haptoglobin, and hemopexin,
the elevations mainly occur at a high tumor burden, above
about 30–40 tumors (Figure 4). Some proteins are highly
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antitrypsin, and others are more consistently elevated, such
as CRP and IL-12. The protein levels are not highly correlated
with each other, but most seem to show occasional elevations
even in the mice with few tumors. Some proteins showed oc-
casional elevations in the wildtypes, including alpha-1-anti-
tyrpsin and IL-1alpha.
Many have proposed using the combined expression of
several markers to achieve improved diagnostic classification
relative to single markers. Many algorithms are available for
sample classification using panels of markers. Here we used
diagonal linear discriminant analysis (DLDA) (Dudoit et al.,
2002) to assign a score that can be used to classify the mice
as eithermutant orwildtype in leave-one-out cross validation.
Panels of five or more of the protein measurements perfectly
separated the samples ( p ¼ 2  1018, rank-sum test,
Figure 5a), as did using just three assays, and classifiers using
two or four assays performed near-perfectly (Supplementary
Figure 1). Surprisingly, the DLDA score was not significantly
Table 2 – Summary of assay development: the detection limits were
determined from the dilution curves of Figure 2
Standard
curve
Dilution
factor
Detection
limit
(pg/ml)
Sandwich assays developed
Anti-mouse haptoglobin Pooled plasma 1:1000 NA
Anti-mouse hemopexin Pooled plasma 1:100000 NA
Anti-mouse
plasminogen
Pooled plasma 1:1000 NA
Anti-mouse CRP Pooled plasma 1:200 NA
Anti-mouse VEGF Recombinant
protein
1:2 1
Anti-mouse IL-12 Recombinant
protein
1:2 30
Anti-mouse MUC-1 Pooled plasma 1:2 NA
Anti-mouse IL-10 Recombinant
protein
1:2 1
Anti-mouse IL-6 Recombinant
protein
1:2 1
Anti-mouse IL-2 Recombinant
protein
1:2 4
Anti-mouse IL-1a Recombinant
protein
1:2 4
Anti-mouse IL-1b Recombinant
protein
1:2 4
Anti-mouse alpha-1
-antitrypsin
Recombinant
protein
1:20 10
Anti-mouse clusterin Pooled plasma 1:20 NA
Sandwich sssays unsuccessful
Anti-human sialyl
Lewis A
Pooled plasma
Anti-human tenascin C Pooled plasma
Anti-human von
Willebrand factor
Pooled plasma
Anti-mouse
troponin C
Recombinant
protein
Anti-mouse MCP-1 Recombinant
protein
Anti-mouse
cytochrome c
Recombinant
proteincorrelated ( p ¼ 0.20) with the number of tumors in the mice
(Figure 5b), meaning that the classification of the young
mice with low tumor burden was at most only slightly more
difficult than the classification of the older mice with higher
tumor burden.
We investigated the importance of each antibody in the
classification by considering the absolute values of the scores
from each antibodywhen using all 12 of them, and calculating
what fraction of the sums of the absolute values of the scores
for each samplewas due to each antibody, on average. The top
three were CRP, haptoglobin, and IL-12, contributing 17%, 14%
and 14% of this sum on average, respectively. By the seventh
best discriminating antibody (IL-10) this average had de-
creased to 8%, while the 11th best antibody (IL-6) contributed
only 3%, and IL-1alpha, which did not show a significant dif-
ference between mutant and wild-type mice, contributed
less than 1% to the sum on average (summarized in Supple-
mentary Figure 2). Therefore no single marker is overwhelm-
ingly influential in the classification, but the proteins with
the highest individual significance play the biggest roles.
3. Discussion
The development of efficient methods to develop and run
multiple sandwich immunoassayswith low sample consump-
tion is critical for the discovery and validation of biomarkers.
Our strategywas different from that of previous efforts, which
multiplexed the detection of multiple analytes using cocktails
of detection antibodies. Instead, we used only one detection
antibody per array and reduced the size and volume of each
array. Since the volume of each assay was low, we could run
multiple assays without a large amount of total sample con-
sumption, and high-throughput processing makes the mea-
surement of many analytes practical. This strategy makes
assay developmentmuch quicker than for multiplexed assays
and removes the possibility of cross-reactivity between
assays.
Others types of low-volume immunoassays have
appeared, such as a microfluidics system that flows liquid by
centrifugal force in a spinning disk (Lai et al., 2004; Honda
et al., 2005). Although studies analyzing sets of real samples
have not appeared on those platforms, in principle a similar
approach of running many low-volume, single-plex assays
could be applied. However, the microfluidics platforms re-
quire significant expertise and specialized laboratories. The
method described here uses equipment that is broadly avail-
able and could be readily adopted by many laboratories.
We demonstrated two sizes of arrays with proportionally
varying numbers of spots, required sample volumes, and
numbers of arrays per slide. Larger arrays might be better
for assay development or initial screening, in which measure-
ments of binding to a large number of antibodies in a limited
number of samples are desired, and smaller arrays could be
preferable for high-throughput measurements on a smaller
number of antibodies. The intra-assay CVs of around 10%
and inter-assay CVs of less than 20% are sufficient for research
applications and similar to many other types of antibody as-
says. The CVs could be further reduced with additional
M O L E C U L A R O N C O L O G Y 1 ( 2 0 0 7 ) 2 1 6 – 2 2 5222Figure 3 – Comparisons of levels in mutant and wildtype mice for selected analytes. (a) Distributions of concentrations. The concentrations of the
indicated analytes for individual samples are indicated by each point, and the box in each plot defines the upper and lower quartiles of the
distributions, with the line in each box indicating the median value. The dashed line in each plot represents the 80% specificity level (5/25 wildtype
samples above the threshold), and the sensitivity at that threshold is given in each plot. (b) Scatter plot comparison of results obtained on larger
arrays (48 arrays/slide) and smaller arrays (192 arrays/slide). The same set of samples was processed in parallel on two microscope slides printed
with the two different array formats.optimization and automation, which may enable diagnostic-
grade applications.
The profiling of the cytokine and acute-phase-reactant
levels revealed a strong systemic inflammatory response in
the mutant mice. That response appears to occur even in
the mice with very low tumor burdens, since the DLDA-
based discrimination performed nearly as well on mice
with few tumors as on those with many tumors, and since
only a few of the individual proteins were positively corre-
lated to tumor burden. These observations may indicate
that a host inflammatory response is present at the earliest
stages of cancer, resulting from small alterations to local tis-
sue architecture. If so, this model may be useful to study the
contribution of the inflammatory host response to tumordevelopment and progression. It is well known that an in-
flammatory environment can drive cancer processes (Cous-
sens and Werb, 2002), and in this case, it may stimulate
mutations in addition to the APC mutation that are needed
for tumor development. More work needs to be done to de-
termine whether the observed plasma protein elevations in-
deed represent a host response to incipient cancer or rather
a general response to the mutation. The analysis of the time
of onset of the inflammatory response, using serially col-
lected samples, would help answer that question. Similar
studies could be used to screen for the onset of tumor-spe-
cific markers. The low-volume methods described here
make such studies possible, since small volumes would be
collected from serial, non-terminal bleeds. Such applications
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cer research studies, since analagous studies are difficult
with human subjects.
CRP is not as strongly induced in mouse as in human in re-
sponse to inflammatory situations (Ku and Mortensen, 1993).
The average CRP elevation in this study was 5.16-fold, com-
pared to an average 13.6-fold elevation found in a recent study
of sera from human lung cancer patients (Gao et al., 2005). Al-
though the level of CRP induction is not as high as in humans,
the consistency of the elevation in mice is very high, showing
a 90% sensitivity for cancer detection at an 80% specificity.
This consistency may indicate a central role for CRP in mouse
inflammatory processes or may reflect the genetic and envi-
ronmental similarity of the mice. Other proteins, such as al-
pha-1-antitrypsin and VEGF, had highly variable levels in the
mutant mice despite the similarities between the mice. Those
proteins also are highly variable in human cancer patients
(Gao et al., 2005). They were not highly important for the clas-
sification of the samples using DLDA, probably because of
their high variability.
Table 3 – Rank-correlations (Spearman’s rho) between protein
concentrations and the indicated parameters
Protein Correlation in
mutants
Correlation in
wildtypes
To number
of tumors
To age To age
CRP 0.030 (0.8) 0.21 (0.2) 0.050 (0.8)
IL-12 L0.30 (0.02) 0.19 (0.2) 0.34 (0.09)
Haptoglobin 0.33 (0.05) 0.43 (0.002) 0.11 (0.6)
Hemopexin 0.47 (0.0005) 0.41 (0.006) 0.12 (0.5)
Plasminogen 0.050 (0.8) 0.010 (0.9) 0.17 (0.4)
IL-2 0.29 (0.06) 0.25 (0.1) L0.51 (0.003)
IL-10 0.19 (0.3) 0.070 (0.7) 0.26 (0.2)
Alpha-1
-antitrypsin
0.010 (1) 0.17 (0.2) L0.38 (0.04)
VEGF 0.020 (0.9) 0.18 (0.3) 0.19 (0.4)
Clusterin 0.13 (0.4) 0.060 (0.7) 0.090 (0.7)
IL-6 0.52 (0.0002) 0.66 (63 10L10 ) 0.20 (0.4)
IL-1alpha 0.19 (0.3) 0.22 (0.18) 0.17 (0.4)
The p-value of the correlation is shown in parentheses. Values with
p  0.05 are in bold type.The elevation of IL-6, haptoglobin, and hemopexin after
the mice show about 30–40 tumors could indicate that these
molecules are important for regulating a heightened stress re-
sponse. The increased levels also could be due to the malab-
sorption secondary to the large tumor burden or the low
level intestinal bleeding known to occur in these mice. Given
that IL-6 has been associated with cachexia (Barton and Mur-
phy, 2001), this model might provide a useful resource for
studying late-stage cancer processes.
The perfect discrimination of the mutant mice from the
wildtype mice using a small number of marker proteins prob-
ably stems from the genetic and environmental similarity of
the mice and their tumors. That level of discrimination would
likely not be possible for human cancer using these proteins.
The sensitive and specific detection of cancer-related abnor-
malities seen here supports the use of mouse models for
new marker discovery. We had no success using anti-human
antibodies to measure mouse proteins, but it would be valu-
able to have antibodies that reacted equally well with the hu-
man andmouse sequences, so that expression levels could be
easily compared between human cancers and mouse models.
In summary, this work demonstrates a practical new ap-
proach for profilingmultiple proteins inmousemodels of can-
cer, and the application of this method revealed the presence
of a consistent inflammatory response even at the earliest
cancer stages. This method could be used to further study
and identify inflammatory mediators of cancer development
and progression. Another logical application of this method
would be to validate candidate biomarkers identified by
mass-spectrometry studies on mouse models of cancer.
Low-volume immunoassay methods also could be useful in
other cases where limited sample is available, such as certain
types of clinical specimens or rare cell populations. The
methods developed here provide a method for the routine
application of antibody-based methods to such studies.
4. Experimental procedures
4.1. Animal husbandry
Mice were purchased from the Jackson Laboratories. Hetero-
zygous APCMin or APC D580 mice on the C57bl/6 (B6)Figure 4 – Protein expression profiles. The samples are arranged in order of increasing tumor burden for the mutant mice. The assays are arranged
in order of increasing p-values from two-sample T-tests comparing the mutant and wild-type mice. Each colored square indicates the fold
differences from the median of all samples for a particular analyte, according to the color bar at left.
M O L E C U L A R O N C O L O G Y 1 ( 2 0 0 7 ) 2 1 6 – 2 2 5224background were mated with wild-type B6 mice. The APCMin
mice contain a nonsense mutation at codon 850, and the
APC D580 mice were created by a targeted deletion of exon
14 of the APC gene resulting in a nonsense mutation at codon
580. The resulting offspring were screened by PCR of tail DNA
using standard methods. Heterozygous APCMin or APC D580
mice were used for the studies. Wild-type age- and sex-
matched littermates were used as controls.
4.2. Plasma collection and tumor quantification
A lethal coma was induced by intraperitoneal injection of
avertin, and blood was removed by cardiac puncture. Blood
was centrifuged at 1500 rpm for 10 min at 4 C in EDTA-coated
tubes. Plasma supernatants were removed and stored at
80 C. The samples were thawed, sub-aliquoted, and re-fro-
zen once prior to analysis. The small and large bowel were re-
moved and opened longitudinally, and the number of tumors
was counted using a dissecting microscope.
4.3. Antibodies
Antibodies were purchased from various sources (Table 1).
The antibodies were prepared at concentrations of 0.5 mg/ml
in 10.1 mmol/l Na2HPO4, 1.8 mmol/l KH2PO4, 137 mmol/l
NaCl, and 2.7 mmol/l KCl (pH 7.5; 1 PBS) containing 0.02%
NaN3. The integrity of each antibody was confirmed by reduc-
ing and non-reducing gel electrophoresis.
4.4. Microarray preparation
A piezoelectric non-contact printer (Biochip Arrayer, Perki-
nElmer Life Sciences) spotted approximately 350 pl of each
Figure 5 – Sample classification. (a) Scores from leave-one-out cross-
validation of diagonal linear discriminant analysis (DLDA) classifiers,
using seven proteins. (b) The DLDA score of each sample is plotted
with respect to the number of tumors in the given sample. The
Spearman’s rho correlation between the two parameters was 0.19
( p[ 0.20).antibody solution onto the surfaces of ultra-thin, nitrocellu-
lose-coated microscope slides (PATH slides, GenTel Biosurfa-
ces). Forty-eight or 192 identical arrays were printed on each
slide, spaced by 4.5 mm or 2.25 mm, respectively. Each array
consisted of 6–36 antibodies and control proteins spotted in
triplicate. A wax border was imprinted around each of the ar-
rays to define hydrophobic boundaries, using a custom-built
device.
4.5. Sandwich assays
Samples (either plasma or purified proteins) were diluted into
1 phosphate-buffered saline (PBS) buffer containing 0.01%
Brij, and 0.01% Tween-20. The microarray slides were washed
in phosphate-buffered saline containing 0.5% Tween-20
(PBST0.5) three times for 3 min each to remove unbound anti-
bodies and clean the surface, and they were placed in a block-
ing solution of PBST0.5 containing 1% BSA at room
temperature for 1 h. The slides were washed in three baths
of PBST0.1 and spun dry. Either 6 or 1.5 ml of sample (and
same volumes for subsequent incubations) were applied to
each array and incubated at room temperature for 1 h. Six mi-
croliters were applied to the larger arrays (on slideswith 48 ar-
rays), and 1.5 ml were applied to the smaller arrays (on slides
with 192 arrays). After washing and spin-drying the slides as
above, 1 ml/ml detection antibody in PBST0.1 containing 0.1%
BSA was applied to each array and incubated at room temper-
ature for 1 h. The slides were washed and spun dry, and 1 ml/
ml streptavidin-phycoerythrin (Roche Applied Science) in
PBST0.1 was applied to each array and incubated at room tem-
perature for 1 h. The slides were given a final wash and dry,
and fluorescence emission was detected at 570 nm using
a microarray scanner (ScanArray Lite, PerkinElmer Life Sci-
ences). All arrays assaying the same protein were scanned in
one sitting at a single laser power and detector gain setting.
The software program GenePix Pro 5.0 (Molecular Devices)
was used to quantify the image data. Median local back-
grounds were subtracted from the median intensity of each
spot, and data from replicate spots were averaged (geometric
mean). The data were not normalized. The reference curves
were created by fitting the fluorescence values using a four-
parameter, non-linear regression curve using the Origin soft-
ware program. The protein concentrations in the samples
were calculated according to the resulting equations.
4.6. Statistical analysis
The data were log-transformed after adding one-tenth of the
mean for each analyte. We compared mutant to wild-type
mouse samples using two-sample T-tests, and estimated
fold-changes based on the means of the log-transformed
data. The original and log-transformed data are available in
the supplementary information (Supplementary Table 1). We
used diagonal linear discriminant analysis (DLDA) to give clas-
sification scores to each sample (Dudoit et al., 2002). We used
leave-one-out-cross-validation of the classifiers, in which
each sample is removed from the data set, one sample at
a time, the best assays (judged by T-tests) and their weights
in the DLDA discriminant function then determined based
MO L E C U L A R O N C O L O G Y 1 ( 2 0 0 7 ) 2 1 6 – 2 2 5 225only on the remaining samples, and the resulting score
computed for the left out sample.
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